Journal of Pharmacogenomics & Pharmacoproteomics

Developing a companion Dx in oncology: From academic research project to companion trial

4^th International conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics

September 22-23, 2016 Phoenix, USA

Anthony Johnson

Empire Genomics LLC, USA

Scientific Tracks Abstracts: J Pharmacogenomics Pharmacoproteomics

Abstract:

This talk will explore the complexities and timelines of licensing a novel genomic technology from Emory University and developing the assay into a companion Dx with a major pharmaceutical partner (Takeda Millennium). We will discuss the process, the key stakeholders as well as key issues that need to be considered and managed in order to ultimately end up with a marketable test in the end. The talk will center on the Empire Genomic Companion Dx assay for proteasome inhibitors in the disease multiple myeloma and the active companion trial NCT02765854. In order to proceed from the bench to the bedside, diagnostic technologies must demonstrate robust scientific data, health economic benefits and the ability to ultimately help clinicians make disease management decisions based on testing results.

Biography :

Anthony Johnson is the President and CEO of Empire Genomics, a leading molecular diagnostic firm specializing in the delivery of precision medicine in the oncology arena. Since the firm’s founding, he has raised multiple rounds of funds, signed multimillion dollar licensing and distribution deals and has developed many companion diagnostic assays that are in clinical development as therapeutic selection markers. He is also a founding partner of Buffalo Biosciences, a life science strategic management services firm, where he consults on areas of healthcare. Previously, he has worked for Invitrogen Corporation, where he created and led the firm’s stem cell and regenerative medicine franchise. He has earned his MBA from the Alliance Manchester Business School in Manchester, England and a Bachelor's degree in Biology from Fisk University in Nashville, Tennessee. He is a Fellow of the second class of the Health Innovators Fellowship and a Member of the Aspen Global Leadership Network.

Email: aljohnson_@msn.com